Clinical trial Recruiting at 1 site Interventional Ages 21 to 60

Mapping and stimulating brain–stomach connections in chronic nausea

Official title: TMS Neuromodulation of Brain-to-Stomach Circuits in Chronic Nausea

Run by University of Pittsburgh · NCT07276035 · Data updated 2026-11-12

This will test whether non-invasive brain stimulation (TMS) can change stomach activity and reduce nausea in adults with chronic nausea and in healthy volunteers.

Quick facts

Study typeInterventional
Ages21 Years to 60 Years
SexAll
Enrollment219 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedJanuary 28, 2026
Main results expectedJuly 2030
Study endsJuly 2031
Registry record updatedJuly 24, 2026
Trial IDNCT07276035 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 21–60 with self-reported chronic nausea and vomiting syndrome or healthy volunteers who meet safety criteria (no implants, no seizure history, BMI ≤30, not pregnant) are ideal candidates.

Probably not a fit

Patients outside the age or BMI range, those with prior gastric surgery, gastric cancer, neurodegenerative disease, a history of seizures, implantable devices, or on excluded medications (e.g., GLP-1 agonists or drugs that lower seizure threshold) are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study uses transcranial magnetic stimulation (TMS) while recording stomach electrical activity with surface electrodes (electrogastrogram, EGG) to identify brain sites that influence the stomach. Researchers will map gastric motor-evoked potentials (GMEPs), apply repetitive TMS to identified hotspots, and measure stomach responses during a satiety task (water load or nutrient drink/meal). Participants include adults with chronic nausea and healthy controls who will attend up to ten in-person visits over several months. Clinical, demographic, and autonomic data (for example EKG) will be collected as covariates to interpret differences between groups.

Why it matters

Potential benefit: If successful, this could lead to a non-invasive way to reduce nausea by targeting brain–stomach pathways.

How similar studies have gone: Related work is relatively novel: small prior studies suggest cortical stimulation can alter gastric rhythms, but clinical benefit for chronic nausea has not been established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults between ages 21-60 years old, with and without CNVS diagnosis per self-report.

Exclusion Criteria:

* body mass index (BMI) \> 30
* pregnancy or intention to become pregnant
* past or present chemotherapy
* diagnosis of gastric (stomach) cancer
* any kind of gastric (stomach) surgery
* current use of GLP-1 receptor agonists (e.g. Ozempic, Trulicity)
* medications which significantly lower seizure thresholds (e.g. bupropion (Wellbutrin), fluoxetine (Prozac), or tramadol (Ultram))
* implantable devices, such as a pacemakers or nerve stimulators
* history of head injury that required hospitalization, metal in the skull, or neurologic disease such as stroke, history of seizures or history of syncope (fainting or passing out)
* neurodegenerative disease (Multiple Sclerosis, Parkinson's or Alzheimer's Disease)
* ongoing psychosis or altered cognitive status status (e.g. hearing sounds or seeing visions that are not there, or feeling confused or suffering from memory lapses)
* history of cardiovascular (i.e., heart attack), pulmonary (i.e., need for supplemental oxygen), or endocrine disease (e.g. diabetes)
* current enrollment in another study using Transcranial Magnetic Stimulation (TMS)
* current use of drugs such as amphetamines, methamphetamine, Ecstasy, Ketamine, Angel Dust/PCP, cocaine, or drinking 3 or more alcoholic drinks per day
* For healthy subjects only: chronic history of gastrointestinal symptoms (e.g., nausea, indigestion, bloating, abdominal pain)
* For CNVS subjects only: diagnosis of gastric motility disorder (e.g. gastroparesis/slow stomach emptying) or history of bowel obstruction (i.e., chronic partial small bowel obstruction)

Where it's running

  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: David J Levinthal, MD PhD — University of Pittsburgh
  • Study coordinator: Elijah D Wright
  • Email: edw87@pitt.edu
  • Phone: 412-647-1228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.